MX339367B - Composicion para tratar tuberculosis en base a perclorato de 4-tioureido-iminometilpiridinio: metodo de preparacion y tratamiento. - Google Patents

Composicion para tratar tuberculosis en base a perclorato de 4-tioureido-iminometilpiridinio: metodo de preparacion y tratamiento.

Info

Publication number
MX339367B
MX339367B MX2012011907A MX2012011907A MX339367B MX 339367 B MX339367 B MX 339367B MX 2012011907 A MX2012011907 A MX 2012011907A MX 2012011907 A MX2012011907 A MX 2012011907A MX 339367 B MX339367 B MX 339367B
Authority
MX
Mexico
Prior art keywords
treatment
new
thioureido
preparation
drug based
Prior art date
Application number
MX2012011907A
Other languages
English (en)
Other versions
MX2012011907A (es
Inventor
Aleksander Sergeevich Gushchin
Tatiana Ivanovna Vinogradova
Petr Kazimirovich Yablonskiy
Gennady Adreevich Batyunin
Natalya Vyacheslavovna Zabolotnyh
Svetlana Nikolaevna Vasilieva
Alexey Vladimirovich Maligin
Original Assignee
Pharmasyntez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44645750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX339367(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmasyntez filed Critical Pharmasyntez
Publication of MX2012011907A publication Critical patent/MX2012011907A/es
Publication of MX339367B publication Critical patent/MX339367B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se relaciona con el área de la industria químico-farmacéutica, específicamente, un nuevo tratamiento contra la tuberculosis que contiene, como ingrediente activo, perclorato de 4-tioureido-iminometilpiridinio a un nivel terapéuticamente efectivo y seguro y excipientes farmacéuticamente aceptables. Además, la presente invención se refiere a un método de preparación del nuevo fármaco, proporcionando un alto rendimiento del nuevo tratamiento. El nuevo tratamiento presenta una actividad tuberculostática más elevada (200 veces más elevada) y una toxicidad más baja (2.4 veces más baja), comparada con un fármaco prototipo, y es estable durante el almacenamiento a largo plazo. Se puede usar el presente medicamento para tratar y prevenir todas las formas de TB pulmonar y extrapulmonar al utilizar el nuevo tratamiento en combinación con otros fármacos para tratar TB.
MX2012011907A 2010-04-20 2011-04-12 Composicion para tratar tuberculosis en base a perclorato de 4-tioureido-iminometilpiridinio: metodo de preparacion y tratamiento. MX339367B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010115705/15A RU2423977C1 (ru) 2010-04-20 2010-04-20 Противотуберкулезное лекарственное средство на основе 4-тиоуреидоиминометилпиридиния перхлората, способ его получения и способ лечения
PCT/IB2011/051566 WO2011132114A2 (en) 2010-04-20 2011-04-12 Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment

Publications (2)

Publication Number Publication Date
MX2012011907A MX2012011907A (es) 2013-03-07
MX339367B true MX339367B (es) 2016-05-20

Family

ID=44645750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011907A MX339367B (es) 2010-04-20 2011-04-12 Composicion para tratar tuberculosis en base a perclorato de 4-tioureido-iminometilpiridinio: metodo de preparacion y tratamiento.

Country Status (16)

Country Link
US (1) US9750727B2 (es)
EP (1) EP2560630A2 (es)
KR (1) KR20130079387A (es)
CN (2) CN105147679A (es)
AP (1) AP3382A (es)
AU (2) AU2011244054A1 (es)
BR (1) BR112012027000A2 (es)
CA (1) CA2794439C (es)
CL (1) CL2012002924A1 (es)
EA (1) EA023213B1 (es)
MX (1) MX339367B (es)
PE (1) PE20130202A1 (es)
RU (1) RU2423977C1 (es)
UA (1) UA102970C2 (es)
WO (1) WO2011132114A2 (es)
ZA (1) ZA201207189B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2735468C1 (ru) * 2019-05-06 2020-11-02 Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИТ" Минздрава России) Способ диагностики туберкулеза почек

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB820196A (en) * 1956-11-28 1959-09-16 Geigy Ag J R Improvements in and relating to therapeutic compositions
US3039925A (en) * 1957-04-24 1962-06-19 Bayer Ag Compositions for the treatment of tuberculosis
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
JPS5946208A (ja) * 1982-08-30 1984-03-15 Daito Koeki Kk 抗菌性組成物
SU1621449A1 (ru) * 1989-04-24 1996-09-10 Иркутский институт органической химии СО АН СССР Перхлорат 4-тиоуреидоиминометилпиридиния, обладающий туберкулостатической активностью
BR0116994A (pt) * 2001-04-27 2004-03-02 Lupin Ltd Um processo aperfeiçoado para a preparação de uma composição que abrange uma combinação de dose fixa (fdc) de quatro drogas antituberculose
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
RU2265014C1 (ru) * 2004-05-13 2005-11-27 Открытое Акционерное Общество "Фармасинтез" Способ получения перхлората 4-тиоуреидоиминометилпиридиния, обладающего туберкулостатической активностью
WO2009004249A1 (fr) * 2007-06-20 2009-01-08 France Telecom Procédé et système d'authentification d'un objet muni d'un dispositif de traitement de données, terminal de communication et programmes d'ordinateur correspondants
RU2360905C2 (ru) * 2007-06-26 2009-07-10 Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук СЕЛЕКТИВНЫЕ ПРОТИВОТУБЕРКУЛЕЗНЫЕ АГЕНТЫ, ПРЕДСТАВЛЯЮЩИЕ СОБОЙ ЗАМЕЩЕННЫЕ 7-АРИЛ(ГЕТЕРИЛ)-6-КАРБЭТОКСИ-4,7-ДИГИДРО-1,2,4-ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ ИЛИ ЗАМЕЩЕННЫЕ 7-АРИЛ(ГЕТЕРИЛ)-4,7-ДИГИДРО-6-НИТРО-1,2,4-ТРИАЗОЛО[1,5-a]ПИРИМИДИНЫ ИЛИ ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ АДДИТИВНЫЕ СОЛИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ПОЛУЧЕНИЯ ЗАМЕЩЕННЫХ 7-АРИЛ(ГЕТЕРИЛ)-6-КАРБЭТОКСИ-5-МЕТИЛ-4,7-ДИГИДРО-1,2,4-ТРИАЗОЛО[1,5-a]ПИРИМИДИНОВ

Also Published As

Publication number Publication date
PE20130202A1 (es) 2013-02-28
EA023213B1 (ru) 2016-05-31
US9750727B2 (en) 2017-09-05
AU2011244054A1 (en) 2012-12-06
EP2560630A2 (en) 2013-02-27
RU2423977C1 (ru) 2011-07-20
CL2012002924A1 (es) 2013-04-12
EA201201308A1 (ru) 2013-02-28
BR112012027000A2 (pt) 2016-07-19
CN102844024A (zh) 2012-12-26
CA2794439C (en) 2015-03-31
WO2011132114A9 (en) 2012-01-26
WO2011132114A3 (en) 2012-03-22
ZA201207189B (en) 2013-05-29
WO2011132114A2 (en) 2011-10-27
CN105147679A (zh) 2015-12-16
AU2016265974A1 (en) 2016-12-15
UA102970C2 (ru) 2013-08-27
AP3382A (en) 2015-07-31
MX2012011907A (es) 2013-03-07
AP2012006486A0 (en) 2012-10-31
KR20130079387A (ko) 2013-07-10
CA2794439A1 (en) 2011-10-27
US20130052265A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
GB2491327A (en) Delayed prolonged drug delivery
GB2491328A (en) Immediate/delayed drug delivery
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
MX338554B (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
NZ605469A (en) Nalbuphine-based formulations and uses thereof
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
WO2012145575A3 (en) Therapy for leukemia
MX2009011900A (es) Curacion de herida diabetica.
MX2019011620A (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
WO2014119985A3 (es) Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
MX339367B (es) Composicion para tratar tuberculosis en base a perclorato de 4-tioureido-iminometilpiridinio: metodo de preparacion y tratamiento.
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну

Legal Events

Date Code Title Description
FG Grant or registration